Table 2.
Stem cell involvement in high grade glioma patient's outcome.
Stem cell marker | Clinical model | Animal model | Association to poor outcome | Ref. | ||
---|---|---|---|---|---|---|
CD133 | Human bulk gliomas | Yes | [43] | |||
CD133 | Gliomas of various grade and histology | Yes | [44] | |||
CD133 | Low-grade and high-grade glioma specimens | Yes | [45] | |||
CD133 | Cell lines from GBM specimens established under neural stem cell conditions | Yes | [46] | |||
CD133 | U251 human glioma cells with knocked-down CD133 | Yes | [47] | |||
CD133 | Two types of GSC within different regions of the same human GBM | No | [48] | |||
Expression signature dominated by HOX genes, which comprises CD133 | GBM from initial surgery or resected at recurrence | Yes | [49] | |||
CD133, Nestin, Sox-2, Musashi-1, CXCR4, Flt-4/VEGFR-3 and CD105/Endoglin | Astrocytomas of different WHO grades | Yes | [50] | |||
Sox2, Musashi-1, nestin | Surgical specimens of human gliomatosis cerebri | Yes | [51] | |||
Renewable neurosphere formation | Cultured human gliomas | Yes | [52] | |||
CD133 | Mouse line whose CD133-expressing cells can be eliminated conditionally | No | [53] | |||
CD133 | Rat C6 cell line | No | [54] | |||
CD133, nestin | Rat N29 and N32 experimental gliomas | Yes | [55] |